Personale

Recapiti

Italiano

Curriculum

Pubblicazioni

Insegnamenti

English

Curriculum

Giacomo COLTRO

Ruolo attuale:: Ricercatore Legge 240/10 a tempo determinato
SSD:: MEDS-09/B - Malattie del sangue
Afferenza organizzativa:: Dipartimento di Medicina Sperimentale e Clinica

Recapiti

giacomo.coltro(AT)unifi.it

Giacomo COLTRO

Curriculum

Educazione

2019 Specializzazione in Ematologia, 60/60 e lode, Università di Firenze, Italia. Tesi: Clinical, Molecular and Prognostic Correlates of Number, Type and Intragenic Localization of TET2 Mutations in Chronic Myelomonocytic Leukemia. Relatore/Correlatore: A.M.Vannucchi/A. Bosi
2019 Research Trainee presso il Cancer Center-Hematology della Mayo Clinic, Rochester, MN (USA). Tutors: Ayalew Teffer/Mrinal Patnaik
2015 Laurea Magistrale in Medicina e Chirurgia, 110/110 e lode, Università degli studi di Padova, Italia. Tesi: Le Mutazioni di CALR: Messa a Punto del Sequenziamento e Implicazioni Cliniche nella Trombocitemia Essenziale. Relatore: Prof. M.L. Randi

Esperienze Professionali

2021 – In corso Ricercatore a tempo determinato tipo a), Centro di Ricerca e Innovazione per le Malattie Mieloproliferative (CRIMM), AOU Careggi, Università di Firenze, Italia
2020 - 2021 Assegnista di ricerca, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative (CRIMM), AOU Careggi, Università di Firenze, Italia

Interessi scientifici

Ricerca clinica e sperimentale nell’ambito delle neoplasie mieloproliferative croniche Philadelphia-.
Caratterizzazione molecolare del profilo di espressione genica nelle neoplasie mieloproliferative.
Studi preclinici e clinici con farmaci innovativi in pazienti con neoplasie mieloproliferative.

Competenze

Diagnosi e trattamento di pazienti con malattie ematologiche oncologiche e non, in particolare neoplasie mieloproliferative croniche.
Esperienza in BSL1, BSL2 e camere bianche, preparazione di colture cellulari in sospensione e adesione (linee cellulari e cellule primarie del paziente), isolamento di popolazioni cellulari specifiche mediante separazione in gradiente di densità, estrazione di acidi nucleici da tessuti, pellet cellulari e sangue intero, purificazione e quantificazione, immunoprecipitazione e western blotting, ELISA e immunoistochimica, PCR, qRT-PCR, HRM, sequenziamento di Sanger.
Utilizzo di software statistici (SPSS, GraphPad, JMP, R) e strumenti bioinformatici. Buona conoscenza dei database online di genomica, trascrittomica e proteomica.
Ottime capacità di relazione e collaborazione con tutte le figure professionali. Ottima capacità di sviluppare e discutere problemi e risultati di attività cliniche e di ricerca, organizzare autonomamente il lavoro clinico e sperimentale e definire le priorità entro le scadenze stabilite.

Didattica

2020-In corso Corso di Ematologia, Facoltà di Medicina e Chirurgia, Università di Firenze, Italia
2020-In corso Corso di Ematologia, Facoltà di Biotecnologie, Università di Firenze, Italia
2020-In corso Corso di Ematologia, Facoltà di Infermieristica, Università di Firenze, Italia

Presentazioni

2020 "RAS / MAPK pathway mutations are associated with adverse survival outcomes and may predict resistance to JAK inhibitors in myelofibrosis.” 25^th Annual edition of the European Hematology Association meeting. Presentazione orale

Premi e riconoscimenti

2019 ASH Abstract Award, " Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients,” 62^nd annual edition of the American Society of Hematology meeting

Finanziamenti

2018- In corso Progetto MYNERVA (MYeloid NEoplasms Research Ven ture AIRC). Coordinatore: Prof. A.M. Vannucchi. Ruolo: Co-Investigator
2019 – In corso Progetto E-MPN (European Myeloproliferative Neoplasms Network). Coordinatori: Prof. A. Reiter, Prof. C.N. Harrison. Ruolo: Co-Investigator
2023- In corso Progetto PRIN (Progetti di Rilevante Interesse Nazionale) bando PNRR (Piano Nazionale di Ripresa e Resilienza) Under 40. Ruolo: Co-Principal Investigator

Studi clinici

2015 – In corso Sub-investigator in oltre 20 trial clinici di fase I/II, III e IV, in particolare in pazienti con neoplasie mieloproliferative, condotti secondo GCP (god clinical practice)

Affiliazioni e professionali

Società Italiana di Ematologia (SIE)
European Hematology Association (EHA)

Capitoli e Libri

Coltro, G., Loscocco, G. G., & Vannucchi, A. M. (2021). Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. International review of cell and molecular biology, 365, 1-69.

Pubblicazioni

Guglielmelli, P., Maccari, C., Sordi, B., Balliu, M., Atanasio, A., Mannarelli, C., ..., Coltro, G., ..., & Vannucchi, A. M. (2023). Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. Blood Cancer Journal, 13(1), 21.
Coltro, G., Sant'Antonio, E., Palumbo, G. A., Mannelli, F., De Stefano, V., Ruggeri, M., ... & Vannucchi, A. M. (2023). Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project. Cancer Medicine.
Coltro, G., Mannelli, F., Loscocco, G. G., Mannarelli, C., Rotunno, G., Maccari, C., ... & Guglielmelli, P. (2022). Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. Blood Cancer Journal, 12(8), 116.
Loscocco, G. G., Guglielmelli, P., Mannelli, F., Mora, B., Mannarelli, C., Rotunno, G., …, Coltro, G., ..., & Vannucchi, A. M. SF3B1 mutations in primary and secondary myelofibrosis: clinical, molecular and prognostic correlates. American journal of hematology.
Loscocco, G. G., Santi, R., Carrai, V., Coltro, G., Mannelli, F., Guglielmelli, P., & Vannucchi, A. M. (2022). Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis. International Journal of Laboratory Hematology.
Mannelli, F., Bencini, S., Coltro, G., Loscocco, G. G., Peruzzi, B., Rotunno, G., ... & Vannucchi, A. M. (2022). Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. American Journal of Hematology.
Guglielmelli, P., Coltro, G., Mannelli, F., Rotunno, G., Loscocco, G. G., Mannarelli, C., ... & Vannucchi, A. M. (2022). ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Blood advances, 6(9), 2927-2931.
Guglielmelli, P., Loscocco, G. G., Mannarelli, C., Rossi, E., Mannelli, F., Ramundo, F., Coltro, G., ... & Vannucchi, A. M. (2021). JAK2V617F variant allele frequency> 50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer Journal, 11(12), 1-9.
Loscocco, G. G., Coltro, G., Guglielmelli, P., & Vannucchi, A. M. (2021). Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells, 10(8), 1962.
Carr, R. M., Vorobyev, D., Lasho, T., Marks, D. L., Tolosa, E. J., Vedder, A., …, Coltro, G., ... & Patnaik, M. M. (2021). RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature communications, 12(1), 1-18.
Guglielmelli, P., Gangat, N., Coltro, G., Lasho, T. L., Loscocco, G. G., Finke, C. M., ... & Tefferi, A. (2021). Mutations and thrombosis in essential thrombocythemia. Blood cancer journal, 11(4), 1-4.
Coltro, G., & Vannucchi, A. M. (2021). The safety of JAK kinase inhibitors for the treatment of myelofibrosis. Expert Opinion on Drug Safety, 20(2), 139-154.
Mangaonkar, A. A., Reichard, K. K., Binder, M., Coltro, G., Lasho, T. L., Carr, R. M., ... & Patnaik, M. M. (2020). Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood advances, 4(21), 5425-5430.
Coltro, G., Rotunno, G., Mannelli, L., Mannarelli, C., Fiaccabrino, S., Romagnoli, S., ... & Patnaik, M. M. (2020). RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 4(15), 3677-3687.
Buradkar, A., Bezerra, E., Coltro, G., Lasho, T. L., Finke, C. M., Gangat, N., ... & Khan, S. (2020). Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia, 1-6.
Antelo, G., Mangaonkar, A. A., Coltro, G., Buradkar, A., Lasho, T. L., Finke, C., ... & Elliott, M. A. (2020). Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T). British journal of haematology, 189(3), e104-e108.
Coltro, G., Mangaonkar, A. A., Lasho, T. L., Finke, C. M., Pophali, P., Carr, R., ... & Robertson, K. D. (2019). Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients. Leukemia, 1-15.
Tefferi, A., Guglielmelli, P., Lasho, T. L., Coltro, G., Finke, C. M., Loscocco, G. G., ... & Hanson, C. A. (2020). Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British journal of haematology, 189(2), 291-302.
Guglielmelli, P., Carobbio, A., Rumi, E., De Stefano, V., Mannelli, L., Mannelli, F., Rotunno, G., Coltro, G., ... & Finazzi, M. C. (2020). Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood cancer journal, 10(2), 1-8.
Coltro, G., Mannelli, F., Vergoni, F., Santi, R., Massi, D., Siliani, L. M., ... & Paoli, C. (2020). Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. Clinical and Experimental Medicine, 1-8.
DiFilippo, E. C., Coltro, G., Carr, R. M., Mangaonkar, A. A., Binder, M., Khan, S. P., ... & Chen, D. (2020). Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia, 1-6.
Li, M., Shah, M., Binder, M., Lasho, T., Carr, R., Mangaonkar, A., Gangat, N., Coltro, G., ... & Patnaik, M. M. (2020). Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. American journal of hematology, 95(2), E31-E34.
Mangaonkar, A. A., Swoboda, D. M., Coltro, G., Lasho, T. L., Novotny, P. J., Pophali, P., ... & Al-Kali, A. (2019). Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia, 1-6.
Coltro, G., Antelo, G., Lasho, T. L., Finke, C. M., Pardanani, A., Gangat, N., ... & Fernandez-Zapico, M. E. (2020). Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. American journal of hematology.
Coltro, G., & Patnaik, M. M. (2019). Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. Current Oncology Reports, 21(11), 101.
Guglielmelli, P., Pacilli, A., Coltro, G., Mannelli, F., Mannelli, L., Contini, E., ... & Scocco, G. L. (2019). Characteristics and clinical correlates of NFE2 mutations in Chronic Myeloproliferative Neoplasms. American journal of hematology.
Tischer, A., Antelo, G., Coltro, G., Finke, C. M., Gonsalves, W., Pardanani, A., ... & Patnaik, M. M. (2019). Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia research, 87, 106264.
Coltro, G., Lasho, T. L., Finke, C. M., Gangat, N., Pardanani, A., Tefferi, A., ... & Patnaik, M. M. (2019). Germline SH2B3 Pathogenic Variant Associated with Myelodysplastic syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. American journal of hematology.
Loscocco, G. G., Mannelli, F., Guglielmelli, P., Paoli, C., Marone, I., Cucci, R., Coltro, G., ... & De Stefano, V. (2019). Italian survey on clinical practice in Myeloproliferative Neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. American journal of hematology.
Tefferi, A., Betti, S., Barraco, D., Mudireddy, M., Shah, S., Hanson, C. A., …, Coltro, G., ... & Guglielmelli, P. (2017). Gender and survival in essential thrombocythemia: A two‐center study of 1,494 patients. American journal of hematology, 92(11), 1193-1197.
Coltro, G., Mannelli, F., Guglielmelli, P., Pacilli, A., Bosi, A., & Vannucchi, A. M. (2017). A life‐threatening ruxolitinib discontinuation syndrome. American journal of hematology, 92(8), 833-838.
Bertozzi, I., Peroni, E., Coltro, G., Bogoni, G., Cosi, E., Santarossa, C., ... & Randi, M. L. (2016). Thrombotic risk correlates with mutational status in true essential thrombocythemia. European journal of clinical investigation, 46(8), 683-689.

Giacomo COLTRO

Pubblicazioni

Legenda

Contributo su rivista |

Articolo su libro |

Libro |

Contributo in atti di convegno (proceeding) |

Brevetto |

Curatela | Altro

Altro |

Tesi di Dottorato

Loscocco, Giuseppe G.; Rotunno, Giada; Mannelli, Francesco; Coltro, Giacomo; Gesullo, Francesca; Pancani, Fabiana; Signori, Leonardo; Maccari, Chiara; Esposito, Maria; Paoli, Chiara; Vannucchi, Alessandro M.; Guglielmelli, Paola (2024). The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 99, pp. 68-78, ISSN:0361-8609 DOI

Coltro, Giacomo; Sant'Antonio, Emanuela; Palumbo, Giuseppe A; Mannelli, Francesco; De Stefano, Valerio; Ruggeri, Marco; Elli, Elena M; Zanotti, Roberta; Borsani, Oscar; Bertozzi, Irene; Duminuco, Andrea; Betti, Silvia; Carli, Giuseppe; Cavalca, Fabrizio; Tanasi, Ilaria; Rumi, Elisa; Randi, Maria L; Garibaldi, Bruno; Loscocco, Giuseppe G; Guglielmelli, Paola; Vannucchi, Alessandro M (2023). Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project. CANCER MEDICINE, vol. 12, pp. 8166-8171, ISSN:2045-7634 DOI

Guglielmelli, Paola; Maccari, Chiara; Sordi, Benedetta; Balliu, Manjola; Atanasio, Alessandro; Mannarelli, Carmela; Capecchi, Giulio; Sestini, Ilaria; Coltro, Giacomo; Loscocco, Giuseppe Gaetano; Rotunno, Giada; Angori, Eva; Borri, Filippo C; Tefferi, Ayalew; Vannucchi, Alessandro M (2023). Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. BLOOD CANCER JOURNAL, vol. 13, pp. 21-21, ISSN:2044-5385 DOI

Coltro, Giacomo; Santi, Raffaella (2023). A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement. BLOOD, vol. 141, pp. 2541-2541, ISSN:1528-0020 DOI

Piccini, Matteo; Mannelli, Francesco; Coltro, Giacomo (2023). The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions. BIOENGINEERING, vol. 10, pp. 591-591, ISSN:2306-5354 DOI

Peroni, Edoardo; Gottardi, Michele; D’Antona, Lucia; Randi, Maria Luigia; Rosato, Antonio; Coltro, Giacomo (2023). Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 24, pp. N/A-N/A, ISSN:1422-0067 DOI

Coltro, Giacomo; Mannelli, Francesco; Loscocco, Giuseppe Gaetano; Mannarelli, Carmela; Rotunno, Giada; Maccari, Chiara; Pancani, Fabiana; Atanasio, Alessandro; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2022). Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. BLOOD CANCER JOURNAL, vol. 12, pp. 1-7, ISSN:2044-5385 DOI

Loscocco, Giuseppe G; Santi, Raffaella; Carrai, Valentina; Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M (2022). Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, pp. 1-2, ISSN:1751-5521 DOI

Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM (2022). Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis. In: American Society of Hematology (ASH) 2022, Blood, pp. 832-833. DOI

Loscocco GG, Santi R, Mannarelli C, Mannelli F, Gesullo F, Coltro G, Guglielmelli P, Gianelli U, Vannucchi AM (2022). Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1%. In: American Society of Hematology (ASH) 2022, Blood, pp. 9714-9716. DOI

Guglielmelli, Paola; Coltro, Giacomo; Mannelli, Francesco; Rotunno, Giada; Loscocco, Giuseppe G; Mannarelli, Carmela; Maccari, Chiara; Paoli, Chiara; Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro M (2022). ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. BLOOD ADVANCES, vol. 6, pp. 2927-2931, ISSN:2473-9537 DOI

Mannelli, Francesco; Bencini, Sara; Coltro, Giacomo; Loscocco, Giuseppe G; Peruzzi, Benedetta; Rotunno, Giada; Maccari, Chiara; Gesullo, Francesca; Borella, Miriam; Paoli, Chiara; Caporale, Roberto; Mannarelli, Carmela; Annunziato, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M (2022). Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. 846-855, ISSN:0361-8609 DOI

Loscocco, Giuseppe G; Guglielmelli, Paola; Mannelli, Francesco; Mora, Barbara; Mannarelli, Carmela; Rotunno, Giada; Pancani, Fabiana; Maccari, Chiara; Bartalucci, Niccolò; Romagnoli, Simone; Coltro, Giacomo; Passamonti, Francesco; Vannucchi, Alessandro M (2022). SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. AMERICAN JOURNAL OF HEMATOLOGY, vol. 97, pp. E347-E349, ISSN:1096-8652 DOI

Carr, Ryan M; Vorobyev, Denis; Lasho, Terra; Marks, David L; Tolosa, Ezequiel J; Vedder, Alexis; Almada, Luciana L; Yurcheko, Andrey; Padioleau, Ismael; Alver, Bonnie; Coltro, Giacomo; Binder, Moritz; Safgren, Stephanie L; Horn, Isaac; You, Xiaona; Solary, Eric; Balasis, Maria E; Berger, Kurt; Hiebert, James; Witzig, Thomas; Buradkar, Ajinkya; Graf, Temeida; Valent, Peter; Mangaonkar, Abhishek A; Robertson, Keith D; Howard, Matthew T; Kaufmann, Scott H; Pin, Christopher; Fernandez-Zapico, Martin E; Geissler, Klaus; Droin, Nathalie; Padron, Eric; Zhang, Jing; Nikolaev, Sergey; Patnaik, Mrinal M (2021). RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. NATURE COMMUNICATIONS, vol. 12, pp. 0-0, ISSN:2041-1723 DOI

Guglielmelli P.; Loscocco G.G.; Mannarelli C.; Rossi E.; Mannelli F.; Ramundo F.; Coltro G.; Betti S.; Maccari C.; Ceglie S.; Chiusolo P.; Paoli C.; Barbui T.; Tefferi A.; De Stefano V.; Vannucchi A.M. (2021). JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. BLOOD CANCER JOURNAL, vol. 11, pp. 199-208, ISSN:2044-5385 DOI

Loscocco G.G.; Coltro G.; Guglielmelli P.; Vannucchi A.M. (2021). Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms. CELLS, vol. 10, pp. 1962-1984, ISSN:2073-4409 DOI

Vannucchi A.M.; Sordi B.; Morettini A.; Nozzoli C.; Poggesi L.; Pieralli F.; Bartoloni A.; Atanasio A.; Miselli F.; Paoli C.; Loscocco G.G.; Fanelli A.; Para O.; Berni A.; Tassinari I.; Zammarchi L.; Maggi L.; Mazzoni A.; Scotti V.; Falchetti G.; Malandrino D.; Luise F.; Millotti G.; Bencini S.; Capone M.; Piccinni M.P.; Annunziato F.; Guglielmelli P.; Mannelli F.; Coltro G.; Fantoni D.; Borella M.; Ravenda E.; Peruzzi B.; Caporale R.; Cosmi L.; Liotta F.; Lombardelli L.; Logiodice F.; Vanni A.; Salvati L.; Lazzeri C.; Bonizzoli M.; Peris A.; Cianchi G.; Bosi A.; Pucatti M.; Fontanari P.; Benemei S.; MatucciCerinic M.; Turco L. (2021). Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. LEUKEMIA, pp. 1121-1133, ISSN:0887-6924 DOI

Coltro G.; Loscocco G.G.; Vannucchi A.M. (2021). Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. ELSEVIER, vol. 365, pp. 1-69, ISSN:0922-3444 DOI

Buradkar, Ajinkya; Bezerra, Evandro; Coltro, Giacomo; Lasho, Terra L; Finke, Christy M; Gangat, Naseema; Carr, Ryan M; Binder, Moritz; Mangaonkar, Abhishek A; Ketterling, Rhett; Khan, Shakila; Rodriguez, Vilmarie; Tefferi, Ayalew; Patnaik, Mrinal M (2021). Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. LEUKEMIA, vol. 35, pp. 644-649, ISSN:0887-6924 DOI

Guglielmelli P.; Gangat N.; Coltro G.; Lasho T.L.; Loscocco G.G.; Finke C.M.; Morsia E.; Sordi B.; Szuber N.; Hanson C.A.; Pardanani A.; Vannucchi A.M.; Tefferi A. (2021). Mutations and thrombosis in essential thrombocythemia. BLOOD CANCER JOURNAL, vol. 11, pp. 77-80, ISSN:2044-5385 DOI

Coltro G.; Vannucchi A.M. (2021). The safety of JAK kinase inhibitors for the treatment of myelofibrosis. EXPERT OPINION ON DRUG SAFETY, vol. 20, pp. 139-154, ISSN:1474-0338 DOI

Coltro, Giacomo; Mannelli, Francesco; Vergoni, Federica; Santi, Raffaella; Massi, Daniela; Siliani, Luisa Margherita; Marzullo, Antonella; Bonifacio, Stefania; Pelo, Elisabetta; Pacilli, Annalisa; Paoli, Chiara; Franci, Annalisa; Calabresi, Laura; Bosi, Alberto; Vannucchi, Alessandro Maria; Guglielmelli, Paola (2020). Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. CLINICAL AND EXPERIMENTAL MEDICINE, pp. 203-210, ISSN:1591-8890 DOI

Coltro, Giacomo; Antelo, Guadalupe; Lasho, Terra L; Finke, Christy M; Pardanani, Animesh; Gangat, Naseema; Carr, Ryan M; Binder, Moritz; Mangaonkar, Abhishek A; Ketterling, Rhett; Fernandez-Zapico, Martin E; Robertson, Keith D; Bosi, Alberto; Vannucchi, Alessandro M; Tefferi, Ayalew; Patnaik, Mrinal M (2020). Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Adult Patients. AMERICAN JOURNAL OF HEMATOLOGY, pp. 222-230, ISSN:0361-8609 DOI

Coltro G.; Rotunno G.; Mannelli L.; Mannarelli C.; Fiaccabrino S.; Romagnoli S.; Bartalucci N.; Ravenda E.; Gelli E.; Sant'Antonio E.; Patnaik M.M.; Tefferi A.; Vannucchi A.M.; Guglielmelli P. (2020). RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. BLOOD ADVANCES, vol. 4, pp. 3677-3687, ISSN:2473-9529 DOI

Guglielmelli P.; Pacilli A.; Coltro G.; Mannelli F.; Mannelli L.; Contini E.; Rotunno G.; Bartalucci N.; Fiaccabrino S.; Sordi B.; Loscocco G.G.; Paoli C.; Vannucchi A.M. (2020). Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. E23-E26, ISSN:0361-8609 DOI

Guglielmelli P.; Carobbio A.; Rumi E.; De Stefano V.; Mannelli L.; Mannelli F.; Rotunno G.; Coltro G.; Betti S.; Cavalloni C.; Finazzi M.C.; Thiele J.; Cazzola M.; Vannucchi A.M.; Barbui T. (2020). Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. BLOOD CANCER JOURNAL, vol. 10, pp. 21-28, ISSN:2044-5385 DOI

Tefferi A.; Guglielmelli P.; Lasho T.L.; Coltro G.; Finke C.M.; Loscocco G.G.; Sordi B.; Szuber N.; Rotunno G.; Pacilli A.; Hanson C.A.; Ketterling R.P.; Pardanani A.; Gangat N.; Vannucchi A.M. (2020). Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. BRITISH JOURNAL OF HAEMATOLOGY, vol. 189, pp. 291-302, ISSN:0007-1048 DOI

Li, Marissa; Shah, Mithun; Binder, Moritz; Lasho, Terra; Carr, Ryan; Mangaonkar, Abhishek; Gangat, Naseema; Coltro, Giacomo; Tefferi, Ayalew; Dao, Linda; Peters, Margot; Chiu, April; Patnaik, Mrinal M (2020). Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. AMERICAN JOURNAL OF HEMATOLOGY, vol. 95, pp. E31-E34, ISSN:0361-8609 DOI

Mangaonkar, Abhishek A; Swoboda, David M; Coltro, Giacomo; Lasho, Terra L; Novotny, Paul J; Pophali, Prateek; Carr, Ryan M; Binder, Moritz; Finke, Christy M; Gangat, Naseema; Al-Kali, Aref; Begna, Kebede H; Reichard, Kaaren K; Ketterling, Rhett P; Al Ali, Najla H; Vafaii, Pardis; Zhang, Ling; Padron, Eric; Talati, Chetasi; Patnaik, Mrinal M (2020). Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. LEUKEMIA, vol. 34, pp. 656-661, ISSN:0887-6924 DOI

Mangaonkar, Abhishek A; Reichard, Kaaren K; Binder, Moritz; Coltro, Giacomo; Lasho, Terra L; Carr, Ryan M; Chiu, April; Negron, Vivian; Hefazi, Mehrdad; Anagnostou, Theodora; Timm, Michael M; Hiebert, James W; Villasboas, Jose C; Gonsalves, Wilson I; Gangat, Naseema; Shah, Mithun; Alkhateeb, Hassan B; Al-Kali, Aref; Elliott, Michelle A; Begna, Kebede H; Wolanskyj-Spinner, Alexandra P; Litzow, Mark R; Hogan, William J; Ansell, Stephen M; Pardanani, Animesh; Tefferi, Ayalew; Patnaik, Mrinal M (2020). Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. BLOOD ADVANCES, vol. 4, pp. 5425-5430, ISSN:2473-9537 DOI

Guadalupe Antelo; Abhishek A. Mangaonkar; Giacomo Coltro; Ajinkya Buradkar; Terra L. Lasho; Christy Finke; Ryan Carr; Moritz Binder; Naseema Gangat; Aref Al‐Kali; Michelle A. Elliott; Rebecca L. King; Matthew Howard; Megan E. Melody; William Hogan; Mark R Litzow; Ayalew Tefferi; Martin E. Fernandez‐Zapico; Rami Komrokji; Mrinal M. Patnaik (2020). Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T). BRITISH JOURNAL OF HAEMATOLOGY, vol. 189, pp. E104-E108, ISSN:0007-1048 DOI

DiFilippo, Emma C; Coltro, Giacomo; Carr, Ryan M; Mangaonkar, Abhishek A; Binder, Moritz; Khan, Shakila P; Rodriguez, Vilmarie; Gangat, Naseema; Wolanskyj, Alexandra; Pruthi, Rajiv K; Chen, Dong; He, Rong; Viswanatha, David S; Lasho, Terra; Finke, Christy; Tefferi, Ayalew; Pardanani, Animesh; Patnaik, Mrinal M (2020). Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. LEUKEMIA, vol. 34, pp. 2519-2524, ISSN:0887-6924 DOI

Tischer, Alexander; Antelo, Guadalupe; Coltro, Giacomo; Finke, Christy M; Gonsalves, Wilson; Pardanani, Animesh; Ketterling, Rhett; Mangaonkar, Abhishek; Gangat, Naseema; Tefferi, Ayalew; Patnaik, Mrinal M; Lasho, Terra L (2019). Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. LEUKEMIA RESEARCH, vol. 87, pp. 0-0, ISSN:0145-2126 DOI

Loscocco G.G.; Mannelli F.; Guglielmelli P.; Paoli C.; Marone I.; Cucci R.; Coltro G.; Sordi B.; Albano F.; Breccia M.; De Stefano V.; Finazzi G.; Iurlo A.; Martino B.; Palandri F.; Passamonti F.; Siragusa S.; Mannelli L.; Fantoni D.; Fazi P.; Amadori S.; Vignetti M.; Barbui T.; Vannucchi A.M. (2019). Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. AMERICAN JOURNAL OF HEMATOLOGY, vol. 94, pp. E239-E242, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Coltro, Giacomo; Mangaonkar, Abhishek A; Lasho, Terra L; Finke, Christy M; Pophali, Prateek; Carr, Ryan; Gangat, Naseema; Binder, Moritz; Pardanani, Animesh; Fernandez-Zapico, Martin; Robertson, Keith D; Bosi, Alberto; Droin, Nathalie; Vannucchi, Alessandro M; Tefferi, Ayalew; Hunter, Anthony; Padron, Eric; Solary, Eric; Patnaik, Mrinal M (2019). Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. LEUKEMIA, pp. 78-85, ISSN:0887-6924 DOI

Coltro, Giacomo; Patnaik, Mrinal M (2019). Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. CURRENT ONCOLOGY REPORTS, vol. 21, pp. 0-0, ISSN:1523-3790 DOI

Coltro, Giacomo; Lasho, Terra L; Finke, Christy M; Gangat, Naseema; Pardanani, Animesh; Tefferi, Ayalew; Jevremovic, Dragan; Altman, Jessica K; Patnaik, Mrinal M (2019). Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. AMERICAN JOURNAL OF HEMATOLOGY, vol. 94, pp. E231-E234, ISSN:0361-8609 DOI

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD (2019). Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs). BLOOD, pp. 0-0, ISSN:0006-4971

Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Pacilli, Annalisa; Bosi, Alberto; Vannucchi, Alessandro Maria (2017). A life-threatening ruxolitinib discontinuation syndrome. AMERICAN JOURNAL OF HEMATOLOGY, pp. 24775-24776, ISSN:0361-8609 DOI

Tefferi, Ayalew; Betti, Silvia; Barraco, Daniela; Mudireddy, Mythri; Shah, Sahrish; Hanson, Curtis A.; Ketterling, Rhett P.; Pardanani, Animesh; Gangat, Naseema; Coltro, Giacomo; Guglielmelli, Paola; Vannucchi, Alessandro M. (2017). Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. AMERICAN JOURNAL OF HEMATOLOGY, vol. 92, pp. 1193-1197, ISSN:0361-8609 DOI Accesso ONLINE all'editore

Bertozzi, Irene; Peroni, Edoardo; Coltro, Giacomo; Bogoni, Giulia; Cosi, Elisabetta; Santarossa, Claudia; Fabris, Fabrizio; Randi, Maria L (2016). Thrombotic risk correlates with mutational status in true essential thrombocythemia. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 46, pp. 683-689, ISSN:0014-2972 DOI

Giacomo COLTRO

Curriculum

Education

2019 Hematology Specialty, 60/60 cum laude, University of Florence, Italy. Thesis: Clinical, Molecular and Prognostic Correlates of Number, Type and Intragenic Localization of TET2 Mutations in Chronic Myelomonocytic Leukemia. Thesis Advisors: Prof. A.M. Vannucchi, MD

2015 Medical Doctor, 110/110 cum laude, University of Padua, Italy. Thesis: CALR Mutations: Sequencing and Clinical Implications in Essential Thrombocythemia. Thesis Advisors: Prof. M.L. Randi, MD

Residency and Fellowship Training

2019 Research Residency at Mayo Clinic, Rochester, MN (USA). Advisors: Dr. Ayalew Tefferi, Dr. Mrinal Patnaik
2015 - 2019 Hematology Residency, University of Florence, Italy

Employment

2021 - Present Type-A Research Fellowship, University of Florence, Italy
2020 - 2021 Research Fellowship, University of Florence, Italy

Scientific interests

Philadelphia-negative chronic myeloproliferative neoplasms (experimental and clinical)
Molecular characterization of gene expression profile in patients with myeloproliferative neoplasms
Preclinical and clinical studies with innovative drugs in patients with myeloproliferative neoplasms

Relevant skills

Diagnosis and treatment of patients with oncological and non-oncological hematological diseases, particularly in the management of patients with chronic myeloproliferative neoplasms.
Experience in BSL1, BSL2 and clean rooms, preparation of cell cultures in suspension and adhesion (cell lines and primary patient cells), isolation of specific cell populations by density gradient separation, extraction of nucleic acids from tissue, cell pellets and whole blood, purification and quantification, immunoprecipitation and western blotting, ELISA and immunohistochemistry, PCR, qRT-PCR, HRM, Sanger sequencing.
Use of statistical software (SPSS, GraphPad, JMP, R) and bioinformatics tools. Good knowledge of online databases in genomics, transcriptomics and proteomics.
Excellent relationship and collaboration skills with all professional figures. Excellent ability to develop and discuss problems and results of clinical and research activities, autonomously organize clinical and experimental work, and define priorities within set deadlines.

Teaching experience

2020-Present Blood diseases, School of Medicine, University of Florence, Italy
2020-Present Blood diseases, Course of Biotechnology, University of Florence, Italy
2020-Present Blood diseases, Course of Nursing, University of Florence, Italy

Presentations

2020 "RAS / MAPK pathway mutations are associated with adverse survival outcomes and may predict resistance to JAK inhibitors in myelofibrosis.” 25^th Annual edition of the European Hematology Association meeting. Oral presentation.

Awards and honors

2019 ASH Abstract Award, " Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients,” 62^nd annual edition of the American Society of Hematology meeting.

Research funding

2018- Present MYNERVA (MYeloid NEoplasms Research Ven ture AIRC) project. Coordinator: Prof. A.M. Vannucchi. Role: Co-Investigator
2019 - Present E-MPN (European Myeloproliferative Neoplasms Network) project. Coordinators: Prof. A. Reiter, Prof. C.N. Harrison. Role: Co-Investigator
2023 - PRIN (Progetti di Rilevante Interesse Nazionale) project - PNRR (Piano Nazionale di Ripresa e Resilienza) Under 40. Role: Co-Principal Investigator

Clinical trials

2015 – Present Sub-investigator in >20 Phase I/II, Phase II and Phase III clinical trials, particularly in patients with myeloproliferative neoplasms, conducted according to the GCP

Professional affiliations and memberships

Italian Society of Hematology (SIE)
European hematology association (EHA)

Book Chapters

Coltro, G., Loscocco, G. G., & Vannucchi, A. M. (2021). Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. International review of cell and molecular biology, 365, 1-69.

Publications

Guglielmelli, P., Maccari, C., Sordi, B., Balliu, M., Atanasio, A., Mannarelli, C., ..., Coltro, G., ..., & Vannucchi, A. M. (2023). Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. Blood Cancer Journal, 13(1), 21.
Coltro, G., Sant'Antonio, E., Palumbo, G. A., Mannelli, F., De Stefano, V., Ruggeri, M., ... & Vannucchi, A. M. (2023). Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project. Cancer Medicine.
Coltro, G., Mannelli, F., Loscocco, G. G., Mannarelli, C., Rotunno, G., Maccari, C., ... & Guglielmelli, P. (2022). Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. Blood Cancer Journal, 12(8), 116.
Loscocco, G. G., Guglielmelli, P., Mannelli, F., Mora, B., Mannarelli, C., Rotunno, G., …, Coltro, G., ..., & Vannucchi, A. M. SF3B1 mutations in primary and secondary myelofibrosis: clinical, molecular and prognostic correlates. American journal of hematology.
Loscocco, G. G., Santi, R., Carrai, V., Coltro, G., Mannelli, F., Guglielmelli, P., & Vannucchi, A. M. (2022). Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis. International Journal of Laboratory Hematology.
Mannelli, F., Bencini, S., Coltro, G., Loscocco, G. G., Peruzzi, B., Rotunno, G., ... & Vannucchi, A. M. (2022). Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. American Journal of Hematology.
Guglielmelli, P., Coltro, G., Mannelli, F., Rotunno, G., Loscocco, G. G., Mannarelli, C., ... & Vannucchi, A. M. (2022). ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Blood advances, 6(9), 2927-2931.
Guglielmelli, P., Loscocco, G. G., Mannarelli, C., Rossi, E., Mannelli, F., Ramundo, F., Coltro, G., ... & Vannucchi, A. M. (2021). JAK2V617F variant allele frequency> 50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer Journal, 11(12), 1-9.
Loscocco, G. G., Coltro, G., Guglielmelli, P., & Vannucchi, A. M. (2021). Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells, 10(8), 1962.
Carr, R. M., Vorobyev, D., Lasho, T., Marks, D. L., Tolosa, E. J., Vedder, A., …, Coltro, G., ... & Patnaik, M. M. (2021). RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature communications, 12(1), 1-18.
Guglielmelli, P., Gangat, N., Coltro, G., Lasho, T. L., Loscocco, G. G., Finke, C. M., ... & Tefferi, A. (2021). Mutations and thrombosis in essential thrombocythemia. Blood cancer journal, 11(4), 1-4.
Coltro, G., & Vannucchi, A. M. (2021). The safety of JAK kinase inhibitors for the treatment of myelofibrosis. Expert Opinion on Drug Safety, 20(2), 139-154.
Mangaonkar, A. A., Reichard, K. K., Binder, M., Coltro, G., Lasho, T. L., Carr, R. M., ... & Patnaik, M. M. (2020). Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood advances, 4(21), 5425-5430.
Coltro, G., Rotunno, G., Mannelli, L., Mannarelli, C., Fiaccabrino, S., Romagnoli, S., ... & Patnaik, M. M. (2020). RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 4(15), 3677-3687.
Buradkar, A., Bezerra, E., Coltro, G., Lasho, T. L., Finke, C. M., Gangat, N., ... & Khan, S. (2020). Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia, 1-6.
Antelo, G., Mangaonkar, A. A., Coltro, G., Buradkar, A., Lasho, T. L., Finke, C., ... & Elliott, M. A. (2020). Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T). British journal of haematology, 189(3), e104-e108.
Coltro, G., Mangaonkar, A. A., Lasho, T. L., Finke, C. M., Pophali, P., Carr, R., ... & Robertson, K. D. (2019). Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients. Leukemia, 1-15.
Tefferi, A., Guglielmelli, P., Lasho, T. L., Coltro, G., Finke, C. M., Loscocco, G. G., ... & Hanson, C. A. (2020). Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British journal of haematology, 189(2), 291-302.
Guglielmelli, P., Carobbio, A., Rumi, E., De Stefano, V., Mannelli, L., Mannelli, F., Rotunno, G., Coltro, G., ... & Finazzi, M. C. (2020). Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood cancer journal, 10(2), 1-8.
Coltro, G., Mannelli, F., Vergoni, F., Santi, R., Massi, D., Siliani, L. M., ... & Paoli, C. (2020). Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. Clinical and Experimental Medicine, 1-8.
DiFilippo, E. C., Coltro, G., Carr, R. M., Mangaonkar, A. A., Binder, M., Khan, S. P., ... & Chen, D. (2020). Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia, 1-6.
Li, M., Shah, M., Binder, M., Lasho, T., Carr, R., Mangaonkar, A., Gangat, N., Coltro, G., ... & Patnaik, M. M. (2020). Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP. American journal of hematology, 95(2), E31-E34.
Mangaonkar, A. A., Swoboda, D. M., Coltro, G., Lasho, T. L., Novotny, P. J., Pophali, P., ... & Al-Kali, A. (2019). Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia, 1-6.
Coltro, G., Antelo, G., Lasho, T. L., Finke, C. M., Pardanani, A., Gangat, N., ... & Fernandez-Zapico, M. E. (2020). Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. American journal of hematology.
Coltro, G., & Patnaik, M. M. (2019). Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. Current Oncology Reports, 21(11), 101.
Guglielmelli, P., Pacilli, A., Coltro, G., Mannelli, F., Mannelli, L., Contini, E., ... & Scocco, G. L. (2019). Characteristics and clinical correlates of NFE2 mutations in Chronic Myeloproliferative Neoplasms. American journal of hematology.
Tischer, A., Antelo, G., Coltro, G., Finke, C. M., Gonsalves, W., Pardanani, A., ... & Patnaik, M. M. (2019). Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. Leukemia research, 87, 106264.
Coltro, G., Lasho, T. L., Finke, C. M., Gangat, N., Pardanani, A., Tefferi, A., ... & Patnaik, M. M. (2019). Germline SH2B3 Pathogenic Variant Associated with Myelodysplastic syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. American journal of hematology.
Loscocco, G. G., Mannelli, F., Guglielmelli, P., Paoli, C., Marone, I., Cucci, R., Coltro, G., ... & De Stefano, V. (2019). Italian survey on clinical practice in Myeloproliferative Neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. American journal of hematology.
Tefferi, A., Betti, S., Barraco, D., Mudireddy, M., Shah, S., Hanson, C. A., …, Coltro, G., ... & Guglielmelli, P. (2017). Gender and survival in essential thrombocythemia: A two‐center study of 1,494 patients. American journal of hematology, 92(11), 1193-1197.
Coltro, G., Mannelli, F., Guglielmelli, P., Pacilli, A., Bosi, A., & Vannucchi, A. M. (2017). A life‐threatening ruxolitinib discontinuation syndrome. American journal of hematology, 92(8), 833-838.
Bertozzi, I., Peroni, E., Coltro, G., Bogoni, G., Cosi, E., Santarossa, C., ... & Randi, M. L. (2016). Thrombotic risk correlates with mutational status in true essential thrombocythemia. European journal of clinical investigation, 46(8), 683-689.